Data Sheet

Product Name:	Ivosidenib
Cat. No.:	HY-18767
CAS No.:	1448347-49-6
Molecular Formula:	$C_{28}H_{22}ClF_3N_6O_3$
Molecular Weight:	582.96
Target:	Isocitrate Dehydrogenase (IDH)
Pathway:	Metabolic Enzyme/Protease
Solubility:	DMSO: ≥ 39 mg/mL



BIOLOGICAL ACTIVITY:

Ivosidenib is a inhibitor of IDH1. The detailed information please refer to WO2015127172A1 and WO2015138839A1.
Target: IDH1

PROTOCOL (Extracted from published papers and Only for reference)

Cell assay [1] The primary AML cells from IDH1 WT patients are cultured in serum–free conditions in the presence of IDH1–IN–1 (0.5 μM, 1 μM, 5 μM) or DMSO. Cell are counted and removed for 2–HG analysis and FACS analysis. Animal administration [2] The Sprague Dawley rats are dosed orally. IDH1–IN–1 concentration in plasma is determined using a sensitive and specific LC/MS method. PK parameters, including AUC and Cmax, are calculated using WinNonlin software.

References:

[1]. Agresta Samuel V, et al. (S)–N–((S)–1–(2–Chlorophenyl)–2–((3,3–difluorocyclobutyl)amino)–2–oxoethyl)–1–(4–cyanopyridin–2–yl)–N–(5–fluoropyridin–3–yl)–5–oxopyrrolidine–2–carboxamide as therapeutically active compound for treating cancer characterized by a mutant allele of IDH1. From PCT Int. Appl. (2015), WO 2015127172 A1 20150827.
[2]. Gu Chong–Hui, et al. Pharmaceutical compositions of therapeutically active compounds comprising (S)–N–((S)–1–(2–chlorophenyl)–2–[(3,3–difluorocyclobutyl)amino]–2–oxoethyl)–1–(4–cyanopyridin–2–yl)–N–(5–fluoropyridin–3–yl)–5–oxopyrrolidine–2–carboxamide for treating hematologic malignancies with mutant allele of IDH1. From PCT Int. Appl. (2015), WO 2015138839 A1 20150917.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA